216 results on '"Nault A"'
Search Results
2. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab
3. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma
4. OS-110 ARMCENVIN: multibipolar radiofrequency ablation of HCC using intratumourous versus extratumourous “no-touch” techniques. French multicentric randomized controlled trial (NCT 01008657)
5. THU-459-YI Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma: a multicentric retrospective study
6. FRI-456 Characterization of the intratumoral immune microenvironment of hepatocellular carcinoma before selective intrahepatic radiation therapy (SIRT) and study of its prognostic value on response to treatment
7. THU-458 No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC
8. OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: the prospective multicentric PET HCC01 study
9. THU-487-YI Upfront multi-bipolar radiofrequency ablation for hepatocarcinoma in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence
10. THU-079 Pre-transplant work-up for acute-on-chronic liver failure patients in intensive care units, a nationwide french survey
11. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target
12. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
13. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA
14. Advances in molecular classification and precision oncology in hepatocellular carcinoma
15. Natural history of liver adenomatosis: A long-term observational study
16. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma
17. The role of molecular enrichment on future therapies in hepatocellular carcinoma
18. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations
19. Molecular classification of hepatocellular adenoma in clinical practice
20. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification
21. Germline and somatic DICER1 mutations in familial and sporadic liver tumors
22. Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma
23. Impact of radiological response and pattern of progression on overall survival in patients with hepatocellular carcinoma treated by atezolizumab-bevacizumab
24. Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile
25. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study
26. Fragility index of positive phase 2 and 3 randomized clinical trials of treatment of hepatocellular carcinoma (2002–2022)
27. Genetic profiling of hepatocellular carcinoma using next-generation sequencing
28. Characterization of a novel PXR isoform with potential dominant-negative properties
29. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma
30. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation
31. Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma
32. Corrigendum to: ‘Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target’ [J Hepatol 2021 (74) 1155-1166]
33. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma
34. Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
35. Milestones in the pathogenesis and management of primary liver cancer
36. Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma
37. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target
38. Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
39. THU-133 - Impact of radiological response and pattern of progression on overall survival in patients with hepatocellular carcinoma treated by atezolizumab-bevacizumab
40. THU-120 - Fragility index of positive phase 2 and 3 randomized clinical trials of treatment of hepatocellular carcinoma (2002–2022)
41. THU-123 - Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile
42. THU-119 - Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study
43. LBO-04 - Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma
44. Combination of meld and lactates predicts early death in patients treated by salvage tips for refractory variceal bleeding
45. BAP1 loss in hepatocellular carcinoma is associated to PKA activation and fibrolamellar features
46. Corrigendum to: “BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA” [J Hepatol (2020) 1–13]
47. Corrigendum to: 'BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA' [J Hepatol (2020) 1–13]
48. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA
49. THU566 - Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma
50. BAP1 loss in hepatocellular carcinoma is associated to PKA activation and fibrolamellar features
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.